Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederglobenewswire.com
GlobeNewswire - Industry News on Biotechnology
Get the latest updates from GlobeNewswire - Industry News on Biotechnology directly as they happen.
Follow now 81 followers
Latest posts
Last updated about 7 hours ago
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about 7 hours ago
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck...
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
about 7 hours ago
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial...
Abivax Presents Third Quarter 2025 Financial Results
about 7 hours ago
Abivax Presents Third Quarter 2025 Financial Results
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
about 7 hours ago
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
about 8 hours ago
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq...
BetaGlue Therapeutics obtient l’autorisation du ministère de la Santé belge pour mener un essai clinique portant sur YntraDose dans le traitement du cancer du pancréas localement avancé non résécable (uLA-PDAC)
about 14 hours ago
MILAN, 15 déc. 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics (« BetaGlue »...
BetaGlue Therapeutics erhält Genehmigung des belgischen Gesundheitsministeriums für klinische Studie mit YntraDose bei inoperablem lokal fortgeschrittenem Bauchspeicheldrüsenkrebs (uLA-PDAC)
about 14 hours ago
MAILAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics („BetaGlue” oder das...
BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
about 14 hours ago
BetaGlue Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in...
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
about 14 hours ago
Promising data show a median overall survival of 18.6 months, with 40%...
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
about 15 hours ago
PharmAla ships MDMA to Mt. Sinai Hospital and starts making patented novel...
FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES YEAR-END REVIEW TO SHAREHOLDERS
about 15 hours ago
WEST PALM BEACH, FL, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies...
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
about 15 hours ago
New PDUFA Target Action Date of January 14, 2026 set by FDA...